Chaudhury Arun, Duvoor Chitharanjan, Reddy Dendi Vijaya Sena, Kraleti Shashank, Chada Aditya, Ravilla Rahul, Marco Asween, Shekhawat Nawal Singh, Montales Maria Theresa, Kuriakose Kevin, Sasapu Appalanaidu, Beebe Alexandria, Patil Naveen, Musham Chaitanya K, Lohani Govinda Prasad, Mirza Wasique
GIM Foundation , Little Rock, AR , USA.
GIM Foundation, Little Rock, AR, USA; University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, USA.
Front Endocrinol (Lausanne). 2017 Jan 24;8:6. doi: 10.3389/fendo.2017.00006. eCollection 2017.
Type 2 diabetes mellitus (T2DM) is a global pandemic, as evident from the global cartographic picture of diabetes by the International Diabetes Federation (http://www.diabetesatlas.org/). Diabetes mellitus is a chronic, progressive, incompletely understood metabolic condition chiefly characterized by hyperglycemia. Impaired insulin secretion, resistance to tissue actions of insulin, or a combination of both are thought to be the commonest reasons contributing to the pathophysiology of T2DM, a spectrum of disease originally arising from tissue insulin resistance and gradually progressing to a state characterized by complete loss of secretory activity of the beta cells of the pancreas. T2DM is a major contributor to the very large rise in the rate of non-communicable diseases affecting developed as well as developing nations. In this mini review, we endeavor to outline the current management principles, including the spectrum of medications that are currently used for pharmacologic management, for lowering the elevated blood glucose in T2DM.
2型糖尿病(T2DM)是一种全球性的流行病,国际糖尿病联合会(http://www.diabetesatlas.org/)发布的全球糖尿病地图清晰地表明了这一点。糖尿病是一种慢性、渐进性且尚未完全了解的代谢性疾病,主要特征是高血糖。胰岛素分泌受损、对胰岛素组织作用的抵抗或两者兼而有之,被认为是导致T2DM病理生理学的最常见原因,T2DM是一种最初由组织胰岛素抵抗引起,逐渐发展为以胰腺β细胞分泌活性完全丧失为特征的疾病谱。T2DM是影响发达国家和发展中国家的非传染性疾病发病率大幅上升的主要原因。在这篇小型综述中,我们努力概述当前的管理原则,包括目前用于药物治疗以降低T2DM患者升高血糖的药物种类。